Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Spain Glycobiology Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Enzymes, Instruments, Reagents, Kits)
5.2.1.1. By Enzyme (Glycosidases & Neuramidases, Glycosyltransferases & Sialytransferases, Carbohydrate Kinases, Carbohydrate Sulfotransferases, Protein Sulfotransferases, Others)
5.2.1.2. By Instruments (HPLC, Antibody arrays, Lectin arrays, MALDI-TOF, Mass spectroscopy, Others)
5.2.1.3. By Reagents (Monosaccharides, Glycoproteins, Oligosaccharides, Others)
5.2.1.4. By Kits (Glycan Releasing Kit, Glycan Labelling Kit, Glycan Purification Kit, Others)
5.2.2. By Application (Drug Discovery, Disease Diagnostics, Virology, Cell Biology, Oncology, Others)
5.2.3. By End User (Research Institutes, Diagnostic Centers, Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Others)
5.2.4. By Region
5.2.5. By Company (2022)
5.3. Market Map
5.3.1. By Product
5.3.2. By Application
5.3.3. By End User
5.3.4. By Region
6. Central Region North Spain Glycobiology Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product (Enzymes, Instruments, Reagents, Kits)
6.2.1.1. By Enzyme (Glycosidases & Neuramidases, Glycosyltransferases & Sialytransferases, Carbohydrate Kinases, Carbohydrate Sulfotransferases, Protein Sulfotransferases, Others)
6.2.1.2. By Instruments (HPLC, Antibody arrays, Lectin arrays, MALDI-TOF, Mass spectroscopy, Others)
6.2.1.3. By Reagents (Monosaccharides, Glycoproteins, Oligosaccharides, Others)
6.2.1.4. By Kits (Glycan Releasing Kit, Glycan Labelling Kit, Glycan Purification Kit, Others)
6.2.2. By Application (Drug Discovery, Disease Diagnostics, Virology, Cell Biology, Oncology, Others)
6.2.3. By End User (Research Institutes, Diagnostic Centers, Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Others)
7. Aragon & Catalonia Glycobiology Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product (Enzymes, Instruments, Reagents, Kits)
7.2.1.1. By Enzyme (Glycosidases & Neuramidases, Glycosyltransferases & Sialytransferases, Carbohydrate Kinases, Carbohydrate Sulfotransferases, Protein Sulfotransferases, Others)
7.2.1.2. By Instruments (HPLC, Antibody arrays, Lectin arrays, MALDI-TOF, Mass spectroscopy, Others)
7.2.1.3. By Reagents (Monosaccharides, Glycoproteins, Oligosaccharides, Others)
7.2.1.4. By Kits (Glycan Releasing Kit, Glycan Labelling Kit, Glycan Purification Kit, Others)
7.2.2. By Application (Drug Discovery, Disease Diagnostics, Virology, Cell Biology, Oncology, Others)
7.2.3. By End User (Research Institutes, Diagnostic Centers, Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Others)
8. Andalusia, Murcia & Valencia Glycobiology Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product (Enzymes, Instruments, Reagents, Kits)
8.2.1.1. By Enzyme (Glycosidases & Neuramidases, Glycosyltransferases & Sialytransferases, Carbohydrate Kinases, Carbohydrate Sulfotransferases, Protein Sulfotransferases, Others)
8.2.1.2. By Instruments (HPLC, Antibody arrays, Lectin arrays, MALDI-TOF, Mass spectroscopy, Others)
8.2.1.3. By Reagents (Monosaccharides, Glycoproteins, Oligosaccharides, Others)
8.2.1.4. By Kits (Glycan Releasing Kit, Glycan Labelling Kit, Glycan Purification Kit, Others)
8.2.2. By Application (Drug Discovery, Disease Diagnostics, Virology, Cell Biology, Oncology, Others)
8.2.3. By End User (Research Institutes, Diagnostic Centers, Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Others)
9. Madrid, Extremadura & Castilla Glycobiology Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product (Enzymes, Instruments, Reagents, Kits)
9.2.1.1. By Enzyme (Glycosidases & Neuramidases, Glycosyltransferases & Sialytransferases, Carbohydrate Kinases, Carbohydrate Sulfotransferases, Protein Sulfotransferases, Others)
9.2.1.2. By Instruments (HPLC, Antibody arrays, Lectin arrays, MALDI-TOF, Mass spectroscopy, Others)
9.2.1.3. By Reagents (Monosaccharides, Glycoproteins, Oligosaccharides, Others)
9.2.1.4. By Kits (Glycan Releasing Kit, Glycan Labelling Kit, Glycan Purification Kit, Others)
9.2.2. By Application (Drug Discovery, Disease Diagnostics, Virology, Cell Biology, Oncology, Others)
9.2.3. By End User (Research Institutes, Diagnostic Centers, Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Others)
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Mergers & Acquisitions
11.3. Product Launches
12. Policy & Regulatory Landscape
13. Porter’s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. Spain Economic Profile
15. Competitive Landscape
15.1. Business Overview
15.2. Product Offerings
15.3. Recent Developments
15.4. Financials (As Reported)
15.5. Key Personnel
15.6. SWOT Analysis
15.6.1. Merck Spain
15.6.2. Agilent Technologies Spain
15.6.3. Thermo Fisher Scientific
15.6.4. New England Biolabs, Inc. (Werfen Espa?a)
15.6.5. Shimadzu Europa GmbH
15.6.6. Asparia Glycomics
15.6.7. Bruker Espa?ola S.A.
15.6.8. Bio - Rad Laboratories
15.6.9. R&D Systems, Inc. (Bio-Techne R&D Systems, S.L.U.)
15.6.10. Danaher Corporation
16. Strategic Recommendations